Breaking News

NeuroDerm Bought for $1.1B

Mitsubishi Tanabe Pharma Corporation acquires lead Phase III Parkinson’s candidate

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mitsubishi Tanabe Pharma Corporation is acquiring Israeli pharma firm NeuroDerm for $1.1 billion. NeuroDerm is a clinical stage company developing drug-device combinations for central nervous system (CNS) disorders. The deal is expected to close in the fourth quarter of 2017. “We believe that this transaction will yield important benefits for NeuroDerm’s shareholders and the Parkinson’s disease patients that urgently need new therapies,” said Oded Lieberman, chief executive officer, NeuroDerm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters